Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antisecretory Factor, Administered as an Enriched Egg Powder, Salovum®, as Supplementary Therapy for Primary Glioblastoma During Concomitant Radio-chemotherapy.

NCT04116138 is registered in ClinicalTrials.gov with Peter Siesjö as lead sponsor.

NCT NCT04116138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04116138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antisecretory Factor, Administered as an Enriched Egg Powder, Salovum®, as Supplementary Therapy for Primary Glioblastoma During Concomitant Radio-chemotherapy.
Lead sponsor
Peter Siesjö
Phase
Phase 1/2
Overall status
Completed
Start date
September 1, 2019
Completion date
March 31, 2021
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral edema, chemotherapy effect, glioblastoma